Gene Therapy for Infectious Diseases

SUMMARY Gene therapy is being investigated as an alternative treatment for a wide range of infectious diseases that are not amenable to standard clinical management. Approaches to gene therapy for infectious diseases can be divided into three broad categories: (i) gene therapies based on nucleic acid moieties, including antisense DNA or RNA, RNA decoys, and catalytic RNA moieties (ribozymes); (ii) protein approaches such as transdominant negative proteins and single-chain antibodies; and (iii) immunotherapeutic approaches involving genetic vaccines or pathogen-specific lymphocytes. It is further possible that combinations of the aforementioned approaches will be used simultaneously to inhibit multiple stages of the life cycle of the infectious agent.

[1]  A. Gervaix,et al.  Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades , 1997, Journal of virology.

[2]  D. Bernstein,et al.  DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. , 1996, Vaccine.

[3]  N. Usman,et al.  Hammerhead ribozyme engineering. , 1996, Current opinion in structural biology.

[4]  M. Colston,et al.  Vaccination against tuberculosis by DNA injection , 1996, Nature Medicine.

[5]  R. Hanecak,et al.  Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes , 1996, Journal of virology.

[6]  J. Burke.  Hairpin ribozyme: current status and future prospects. , 1996, Biochemical Society transactions.

[7]  Donna L. Montgomery,et al.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.

[8]  R. Purcell,et al.  DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Inouye,et al.  Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus , 1996, Antimicrobial agents and chemotherapy.

[10]  V. Zurawski,et al.  Expression and immune response to hepatitis C virus core DNA–based vaccine constructs , 1996, Hepatology.

[11]  R. Morgan,et al.  Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. , 1996, Human gene therapy.

[12]  D. Bernstein,et al.  DNA immunization against experimental genital herpes simplex virus infection. , 1996, The Journal of infectious diseases.

[13]  B. Plachter,et al.  Stably expressed antisense RNA to cytomegalovirus UL83 inhibits viral replication , 1996, Journal of virology.

[14]  J. Hauber,et al.  Inhibition of HIV-1 Replication in Lymphocytes by Mutants of the Rev Cofactor eIF-5A , 1996, Science.

[15]  M. Weil,et al.  Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. , 1995, Cancer gene therapy.

[16]  L. Aurelian,et al.  Inhibition of herpes simplex virus replication by antisense oligo-2'-O-methylribonucleoside methylphosphonates. , 1995, Biochemistry.

[17]  M. Daucher,et al.  Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics. , 1995, AIDS research and human retroviruses.

[18]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[19]  P. Hofschneider,et al.  Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides , 1995, Hepatology.

[20]  N. Kato,et al.  Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. , 1995, Biochemical and biophysical research communications.

[21]  M. Reitz,et al.  Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro , 1995, Nature Medicine.

[22]  R. Morgan,et al.  Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes , 1995, Journal of virology.

[23]  J. Shiver,et al.  Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus , 1995, Nature Medicine.

[24]  G. Davis,et al.  Relationship between the presence of circulating anti-GOR and hepatitis C viremia/genotype. , 1995, Journal of hepatology.

[25]  D. Fuller,et al.  Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. , 1995, Virology.

[26]  G. Pari,et al.  Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37 , 1995, Antimicrobial agents and chemotherapy.

[27]  I. Plavec,et al.  RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells. , 1995, Human gene therapy.

[28]  J. Lisziewicz,et al.  Antitat gene therapy: a candidate for late-stage AIDS patients. , 1995, Gene therapy.

[29]  L. Donehower,et al.  Inhibition of HIV-1 by a double transdominant fusion gene. , 1995, Gene therapy.

[30]  M. Linial,et al.  Inhibition of wild-type HIV-1 virus production by a matrix deficient Gag mutant. , 1995, Virology.

[31]  J. Bagley,et al.  Inhibition of HIV‐1 Tat‐mediated LTR transactivation and HIV‐1 infection by anti‐Tat single chain intrabodies. , 1995, The EMBO journal.

[32]  S. Chan,et al.  Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre‐S components of the HBV coat protein with non pre‐S containing vaccines , 1995, Journal of gastroenterology and hepatology.

[33]  J. Lieberman,et al.  Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. , 1995, AIDS research and human retroviruses.

[34]  E. Gilboa,et al.  Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain , 1994, Journal of virology.

[35]  S. Chatterjee,et al.  Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. , 1994, Cancer gene therapy.

[36]  R. Morgan,et al.  Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. , 1994, Human gene therapy.

[37]  M J Sheehy,et al.  Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Anderson,et al.  Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1. , 1994, AIDS research and human retroviruses.

[39]  E. Poeschla,et al.  Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. , 1994, Human gene therapy.

[40]  S. Chada,et al.  Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates , 1994, Journal of virology.

[41]  G. F. Joyce,et al.  Inventing and improving ribozyme function: rational design versus iterative selection methods. , 1994, Trends in biotechnology.

[42]  B. Howard,et al.  Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins. , 1994, Human gene therapy.

[43]  O. Bagasra,et al.  Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Chen,et al.  Intracellular antibodies as a new class of therapeutic molecules for gene therapy. , 1994, Human gene therapy.

[45]  R. Krance,et al.  Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, Tennesse , 1994 .

[46]  W. F. Anderson.  Gene therapy for AIDS. , 1994, Human gene therapy.

[47]  T. Cech,et al.  Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. , 1993, Science.

[48]  J. Hauber,et al.  Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans- activation , 1993, The Journal of cell biology.

[49]  A. Ramezani,et al.  The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. , 1993, Human gene therapy.

[50]  H. Lane,et al.  A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. , 1993, Human gene therapy.

[51]  C. Richards,et al.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. , 1993, Cancer research.

[52]  J. Sinclair,et al.  Inhibition of human cytomegalovirus major immediate early gene expression by antisense RNA expression vectors. , 1993, The Journal of general virology.

[53]  R. Crooke,et al.  Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region , 1993, Antimicrobial Agents and Chemotherapy.

[54]  J. Lisziewicz,et al.  Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Chen,et al.  Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  S. Riddell,et al.  CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. , 1993, Current opinion in immunology.

[57]  C. Stein,et al.  Antisense Nucleic Acids — Prospects for Antiviral Intervention , 1993 .

[58]  Y. Cheng,et al.  Potent inhibition of Epstein-Barr virus by phosphorothioate oligodeoxynucleotides without sequence specification , 1993, Antimicrobial Agents and Chemotherapy.

[59]  O. Yamada,et al.  A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Zhou,et al.  Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes , 1993, Journal of virology.

[61]  S. Chang,et al.  Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes , 1993, Journal of virology.

[62]  L. Cowsert,et al.  Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. , 1993, Cancer research.

[63]  J. Lisziewicz,et al.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[64]  W. Greene,et al.  Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo , 1993, Journal of virology.

[65]  J. Kreider,et al.  Cleavage of cottontail rabbit papillomavirus E7 RNA with an anti-E7 ribozyme. , 1993, Biochemical and biophysical research communications.

[66]  Z. Matsuda,et al.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Rose,et al.  Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[69]  J. Mcdougal,et al.  Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4 , 1993, Journal of virology.

[70]  H. Blum,et al.  In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. , 1993, The EMBO journal.

[71]  G. Zon,et al.  In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts , 1993, Antimicrobial Agents and Chemotherapy.

[72]  W F Anderson,et al.  Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. , 1993, Human gene therapy.

[73]  B. Sproat,et al.  Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. , 1993, Journal of medicinal chemistry.

[74]  G. Pavlakis,et al.  Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression , 1992, Journal of virology.

[75]  J. Lisziewicz,et al.  Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[76]  P. Johnson,et al.  Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. , 1992, Science.

[77]  P. Barr,et al.  In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription. , 1992, Nucleic acids research.

[78]  J. Ojwang,et al.  Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[79]  P. C. Weber,et al.  Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0. , 1992, The Journal of general virology.

[80]  M. Malim,et al.  Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication , 1992, The Journal of experimental medicine.

[81]  R. Husson,et al.  Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection. , 1992, The Journal of pediatrics.

[82]  J. Pagano,et al.  Epstein‐Barr Viral Latency and Cell Immortalization as Targets for Antisense Oligomers a , 1992, Annals of the New York Academy of Sciences.

[83]  T. Curiel,et al.  Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. , 1992, Human gene therapy.

[84]  A. Banerjea,et al.  Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates. , 1992, Nucleic acids research.

[85]  M. Pawlita,et al.  Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis , 1992, Journal of virology.

[86]  K. Adler‐Storthz,et al.  Effect on cancer cells of plasmids that express antisense RNA of human papillomavirus type 18. , 1992, Cancer research.

[87]  S. Chada,et al.  CTL cross reactivity between HIV strains. , 1992, AIDS research and human retroviruses.

[88]  E. Freed,et al.  Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. , 1992, Human gene therapy.

[89]  Z. Matsuda,et al.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions , 1992, Journal of virology.

[90]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[91]  M. von Knebel Doeberitz,et al.  Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV e6‐e7 anti‐sense RNA , 1992, International journal of cancer.

[92]  C. Wu,et al.  Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. , 1992, The Journal of biological chemistry.

[93]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[94]  M. Feinberg,et al.  Intracellular immunization: trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication. , 1992, AIDS research and human retroviruses.

[95]  S. Riddell,et al.  Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington , 1992 .

[96]  T. Hope,et al.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes , 1992, Journal of virology.

[97]  M. Maki,et al.  Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev , 1992, Journal of virology.

[98]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[99]  M. Martin,et al.  Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression , 1992, Journal of virology.

[100]  J. Rossi,et al.  Ribozymes as anti-HIV-1 therapeutic agents: principles, applications, and problems. , 1992, AIDS research and human retroviruses.

[101]  G. Pavlakis,et al.  Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein , 1992, Journal of virology.

[102]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[103]  K. Anderson,et al.  In vitro and in vivo pharmacologic activities of antisense oligonucleotides. , 1991, Anti-cancer drug design.

[104]  T. Merigan,et al.  Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection. , 1991, Immunology.

[105]  B. Sullenger,et al.  Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation , 1991, Journal of virology.

[106]  S. Read,et al.  Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme , 1991, Journal of virology.

[107]  A. Bernstein,et al.  Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression , 1991, Journal of virology.

[108]  S. Riddell,et al.  Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. , 1991, Blood.

[109]  T. Crook,et al.  Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. , 1991, Nucleic acids research.

[110]  C. Debouck,et al.  Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. , 1991, The New biologist.

[111]  M. Malim,et al.  Mutational definition of the human immunodeficiency virus type 1 Rev activation domain , 1991, Journal of virology.

[112]  S. Chada,et al.  Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. , 1991, AIDS research and human retroviruses.

[113]  A. Bono.  Gene Therapy For Aids? , 1991, Bio/Technology.

[114]  M. A. Hardwicke,et al.  Mutations in the activation region of herpes simplex virus regulatory protein ICP27 can be trans dominant , 1991, Journal of virology.

[115]  D. Knipe,et al.  Potential role for herpes simplex virus ICP8 DNA replication protein in stimulation of late gene expression , 1991, Journal of virology.

[116]  W. Britt,et al.  Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. , 1991, Journal of immunology.

[117]  G. Sczakiel,et al.  Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. , 1991, Nucleic acids research.

[118]  D. Ho,et al.  Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. , 1991, The American journal of medicine.

[119]  S. Johnston,et al.  Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[120]  A. Rhodes,et al.  Inhibition of heterologous strains of HIV by antisense RNA. , 1991, AIDS.

[121]  M. Pawlita,et al.  Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA , 1991, Journal of virology.

[122]  K. Watabe,et al.  Antisense oligodeoxyribonucleotides inhibit the expression of the gene for hepatitis B virus surface antigen. , 1990, The Journal of general virology.

[123]  T. Werge,et al.  Intracellular immunization , 1990, FEBS letters.

[124]  Eli Gilboa,et al.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication , 1990, Cell.

[125]  A. Rhodes,et al.  Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. , 1990, The Journal of general virology.

[126]  D. Ho,et al.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[127]  N. DeLuca,et al.  trans-dominant inhibition of herpes simplex virus transcriptional regulatory protein ICP4 by heterodimer formation , 1990, Journal of virology.

[128]  J. Rose,et al.  Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum , 1990, Nature.

[129]  P. Sharp,et al.  Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[130]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[131]  J. Rossi,et al.  Ribozymes as potential anti-HIV-1 therapeutic agents. , 1990, Science.

[132]  R. Schooley,et al.  Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. , 1990, Annals of internal medicine.

[133]  W. Anderson,et al.  Retroviral vectors expressing soluble CD4: a potential gene therapy for AIDS. , 1990, AIDS research and human retroviruses.

[134]  A. Régnault,et al.  Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV‐1 by deletion of the env amino‐terminal signal sequence , 1990, European journal of immunology.

[135]  B. Guy,et al.  An antigenic peptide of the HIV‐1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA‐B , 1989, European journal of immunology.

[136]  D. Baltimore,et al.  HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus , 1989, Cell.

[137]  M. Ishino,et al.  Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression , 1989, Cell.

[138]  M. Malim,et al.  Functional dissection of the HIV-1 Rev trans-activator—Derivation of a trans-dominant repressor of Rev function , 1989, Cell.

[139]  D. Bednarik,et al.  Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[140]  B. Guy,et al.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins , 1989, Journal of virology.

[141]  E. Gilboa,et al.  Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA , 1989, Journal of virology.

[142]  D. Baltimore.  Intracellular immunization , 1988, Nature.

[143]  B. Moss,et al.  A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[144]  B. Walker,et al.  HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. , 1988, Science.

[145]  R. Siliciano,et al.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation , 1988, Nature.

[146]  W. Lüke,et al.  Soluble CD4 molecules neutralize human immunodeficiency virus type 1 , 1988, Nature.

[147]  B. Walker,et al.  HIV infection is blocked in vitro by recombinant soluble CD4 , 1988, Nature.

[148]  R. Axel,et al.  soluble form of CD4 (T4) protein inhibits AIDS virus infection , 1988, Nature.

[149]  U. Koszinowski,et al.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity , 1987, Journal of virology.

[150]  I. Herskowitz.  Functional inactivation of genes by dominant negative mutations , 1987, Nature.

[151]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[152]  S. Jonjić,et al.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs , 1985, Journal of virology.

[153]  Z. Chen,et al.  Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavirus type 18. , 1996, Cancer gene therapy.

[154]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.

[155]  B. Rouse,et al.  Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27. , 1995, Viral immunology.

[156]  S. Riddell,et al.  Principles for adoptive T cell therapy of human viral diseases. , 1995, Annual review of immunology.

[157]  R. Krance,et al.  Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. , 1994, Human gene therapy.

[158]  J. Yee,et al.  Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. , 1994, Gene therapy.

[159]  S. Lam,et al.  Effects of human papillomavirus type-specific antisense oligonucleotides on cervical cancer cells containing papillomavirus type 16 , 1994, Medical oncology.

[160]  B. Fox,et al.  A molecular genetic intervention for AIDS--effects of a transdominant negative form of Rev. , 1994, Human gene therapy.

[161]  M. Blumenfeld,et al.  Improved anti-herpes simplex virus type 1 activity of a phosphodiester antisense oligonucleotide containing a 3'-terminal hairpin-like structure. , 1994, Antisense research and development.

[162]  D. Chadwick,et al.  Vaccines against virally induced cancers , 1994 .

[163]  J. Jaroszewski,et al.  A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. , 1992, Antiviral research.

[164]  T. Lee,et al.  Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. , 1992, The New biologist.

[165]  S. Agrawal,et al.  GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. , 1992, Antisense research and development.

[166]  R. Blaese,et al.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[167]  D. Klatzmann,et al.  Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[168]  J. Lisziewicz,et al.  Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. , 1991, The New biologist.

[169]  D. Jolly,et al.  Induction of anti-HIV-1 immune responses by retroviral vectors. , 1991, Biotechnology therapeutics.

[170]  Jolly Dj,et al.  Induction of anti-HIV-1 immune responses by retroviral vectors. , 1991 .